Key Highlights: Implications: This approval moves Enhertu + Perjeta into the front line of HER2‑positive metastatic breast cancer care in India, displacing taxane + tra...
Key Highlights: Implications: Imfinzi storms endometrial cancer protocols, giving oncologists a potent immunotherapy combo that leapfrogs chemo-only standards. AstraZeneca doubles do...
Key Highlights: Implications: Durvalumab storms earlier gastric cancer treatment, snatching share from chemo-only protocols as oncologists embrace immunotherapy combo superiority.&nb...
